Related Experiment Video

Updated: Jan 15, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K

Progressive multifocal leukoencephalopathy and BK virus-nephropathy with bispecific antibody therapy in multiple

Ariel Siegel1, Sidorela Reci1, Leah Grossman1

  • 1Tisch Cancer Institute, Department of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York.

Haematologica
|October 9, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
11:54

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry

Published on: July 13, 2019

9.4K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.0K

Related Experiment Videos

Last Updated: Jan 15, 2026

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
10:19

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

1.6K
Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry
11:54

Measurement of BK-polyomavirus Non-Coding Control Region Driven Transcriptional Activity Via Flow Cytometry

Published on: July 13, 2019

9.4K
In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells
10:26

In Vitro Differentiation Model of Human Normal Memory B Cells to Long-lived Plasma Cells

Published on: January 20, 2019

13.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K

Articles linked to this work by shared authors, journal, and citation graph.

Eschar in scrub typhus: clinical signature, immunopathogenesis, and diagnostic implications.

Clinical microbiology reviews·2026

Microtubule and cytoskeletal destabilization gene expression in the brain vasculature after experimental diffuse traumatic brain injury: Implications for neurodegenerative disease later in life.

Neuroscience letters·2026

Learning from relapse: how MajesTEC-1 immune profiling points the way to next-generation bispecific strategies.

Haematologica·2026

Distinct site-specific bacterial microbiota within and between skin physiologic types in healthy Koreans: a pilot study.

Scientific reports·2026

Emapalumab and eltrombopag rescue for prolonged immune effector cell-associated hemophagocytic syndrome after CAR T-cell therapy in multiple myeloma.

Haematologica·2026

Genomic features of clonal hematopoiesis-associated genes in primary and CAR T-cell-related secondary T-cell malignancies.

Blood neoplasia·2026

Prognostic significance of monotypic plasma cell infiltration of the bone marrow in patients with Waldenström macroglobulinemia.

Haematologica·2026

Impact of maintenance therapy on survival after autologous stem cell transplant for multiple myeloma regardless of response: a global analysis.

Haematologica·2026

Protecting sickle cell care during Ebola outbreaks.

Haematologica·2026

Epstein-Barr virus reactivation and post-transplant lymphoproliferative disease risk deserve a place in the JAK inhibitor toxicity profile. Comment on: "Janus kinase inhibitors as an evolving treatment for lymphomas and immune-mediated complications".

Haematologica·2026

T-cell lymphoma following chimeric antigen receptor-T therapy: a cause for concern?

Haematologica·2026

Epidemiology of respiratory viral infections among hematopoietic cellular therapy and chimeric antigen receptor T-cell therapy recipients in the post COVID-19 era.

Haematologica·2026

[Research progress and application status of nanobody-drug conjugate(NDC) in cancer treatment].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology·2026

Biohybrid M13 phage backpacks for active blood-brain barrier traversal and precision central nervous system leukemia treatment.

Biomarker research·2026

Cryptococcal meningitis with cerebrospinal fluid human immunodeficiency virus escape presenting as transient diplopia and areflexia.

BMJ case reports·2026

Phytochemical-mediated targeting of signaling pathways in glioblastoma: preclinical evidence, translational potential, and emerging nano-based therapeutic approaches.

The Journal of pharmacy and pharmacology·2026

Lipid Co-Loaded with PGRN and NATA Demonstrated Significantly Enhanced Antifungal and Anti-Inflammatory Activities in the Treatment of Fungal Keratitis.

International journal of nanomedicine·2026

Innovations, implementation, and challenges of mobile health: a narrative review.

Frontiers in public health·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us